Study of Model Use for Determining Potential Company Sales and Company Decision Behavior for Mazda of Stillwater as Viewed from a Marketing Research Perspective

The purpose of the study was to examine the potential sales of a newly franchised automobile dealer in a relatively small community such as Stillwater, Oklahoma. In order to accomplish this various marketing models were examined after the economic environment of the nation was analyzed with particular emphasis on the recent developments brought about by the energy crisis. The overall tone of the study was one of guarded optimism. The optimism was shown in the industry model where sales for the entire automobile industry were examined and small car sales were seen to be on the rise. The operation and expansion of the Toyo Kogyo Company of Japan was covered in the company model. The company started mass producing rotary engines in 1967 and marketed them to the Mazda automobile. Mazda's competitive position was examined the competitive model. In this model, Mazda's relation to the industry was analyzed and the entry of other automobile manufacturers into the rotary engine field was explored. The costs of inventory acquisition and storage were presented in the channel model. Then the market share model for Stillwater was given. The model viewed the demographic characteristics of the community as they affect advertising and market strategy of the Mazda dealer. As the energy crisis has taken its toll on the economy, the American public has turned to small cars as a means of reducing gas consumption. Small car sales account for more than 50 percent of all autos currently being sold. Mazda, since it was introduced into the U.S. in 1970, has experienced phenomenal growth in sales which should continue in the future. Mazda's sales in Stillwater, however, have been very slow. If this Stillwater dealer is to prosper, he must alter his operations and aggressively seek to expand sales through the judicious use of advertising and salesmanship. He must overcome a poor location, find a qualified salesman, and establish a firm advertising budget. If he continues operations as they are now, his business survival is in jeopardy.Business Administratio

Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry

AIMS: Calmodulinopathy due to mutations in any of the three CALM genes (CALM1-3) causes life-threatening arrhythmia syndromes, especially in young individuals. The International Calmodulinopathy Registry (ICalmR) aims to define and link the increasing complexity of the clinical presentation to the underlying molecular mechanisms. METHODS AND RESULTS: The ICalmR is an international, collaborative, observational study, assembling and analysing clinical and genetic data on CALM-positive patients. The ICalmR has enrolled 140 subjects (median age 10.8 years [interquartile range 5-19]), 97 index cases and 43 family members. CALM-LQTS and CALM-CPVT are the prevalent phenotypes. Primary neurological manifestations, unrelated to post-anoxic sequelae, manifested in 20 patients. Calmodulinopathy remains associated with a high arrhythmic event rate (symptomatic patients, n = 103, 74%). However, compared with the original 2019 cohort, there was a reduced frequency and severity of all cardiac events (61% vs. 85%; P = .001) and sudden death (9% vs. 27%; P = .008). Data on therapy do not allow definitive recommendations. Cardiac structural abnormalities, either cardiomyopathy or congenital heart defects, are present in 30% of patients, mainly CALM-LQTS, and lethal cases of heart failure have occurred. The number of familial cases and of families with strikingly different phenotypes is increasing. CONCLUSION: Calmodulinopathy has pleiotropic presentations, from channelopathy to syndromic forms. Clinical severity ranges from the early onset of life-threatening arrhythmias to the absence of symptoms, and the percentage of milder and familial forms is increasing. There are no hard data to guide therapy, and current management includes pharmacological and surgical antiadrenergic interventions with sodium channel blockers often accompanied by an implantable cardioverter-defibrillator